A multicenter, phase II study of cisplatin, irinotecan and epirubicin (PIE) administered every 3 weeks in patients with unresectable, locally advanced/metastatic cervical carcinoma. Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Townsley, CA
  • Elit, Laurie
  • Carey, M
  • Afinec, A
  • Tinker, L
  • Sturgeon, J
  • Oza, AM

publication date

  • June 1, 2005